2 Reasons It's Not Too Late to Buy Moderna

On Nov. 30, the company announced that it was filing for Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Shares of Moderna ultimately doubled over the month of November, going from less than $68 as of the end of October to more than $140 on Nov. 30. There's a lot of reason to be bullish about Moderna right now, and while investors may want to cash out some of their gains, the stock may continue to rise even higher in the weeks and months ahead.